Theranos

She had every reason to panic. Instead, she tilted her chin slightly upward and said: "You know, people try to take advantage of situations like this. We know what we're doing and we're very proud of it."

The audience applauded.

Four months later, Forbes dropped her net worth from $4.5 billion to zero.

Elizabeth Holmes was nineteen years old when she dropped out of Stanford in 2003. She'd been studying chemical engineering. She had an idea: a wearable patch that could monitor a patient's blood and adjust drug dosages in real time — notifying doctors when something went wrong. She pitched it to her professor, Channing Robertson, who was skeptical. But he was also intrigued enough to join the company as its first board member.

She founded Real-Time Cures first. Changed the name to Theranos — therapy + diagnosis — after deciding that "cure" made people skeptical.

By December 2004, she'd raised $6 million. By 2010, $92 million in venture capital. She operated in near-total secrecy, speaking rarely to press, projecting the persona of a visionary who simply had no time for questions.

The pitch was straightforward and seductive: what if blood tests — the kind that require vials of blood drawn from your arm, the kind you wait days for, the kind that cost hundreds of dollars — could be done with a finger prick? A few drops? Instantly? At a fraction of the cost?

Holmes named the device the Edison. When asked why, she said it was after Thomas Edison — the inventor who famously said "I've not failed. I've just found 10,000 ways that won't work."

Here's what Theranos claimed: a device called the Edison that could run dozens of blood tests from a finger prick, using proprietary microfluidics, with results as accurate as traditional lab testing. It would sit in a clinic, require only a few drops of blood, and deliver results in minutes.

Here's what the engineering reality looked like:

The Edison was not ready. It was not close to ready. By the company's own later admission, the device could reliably perform only 12 tests — out of more than 200 that Theranos was advertising on its patient menu.

When Theranos ran patient tests, it was using traditional venous blood draws and standard commercial machines, mostly Siemens devices. It told investors this wasn't happening. When patients got results, they were sometimes wildly off — a problem that matters enormously when you're testing for conditions like warfarin levels, where an inaccurate result can kill.

Internal employees knew. In 2013, a Theranos scientist named Ian Gibbons — who had been brought on specifically because he had expertise in the type of technology Holmes claimed to have built — tried to raise concerns internally. He was ignored. He was later told not to talk to certain colleagues. He died by suicide in 2014.

The company built a fake lab. When Vice President Joe Biden toured the Theranos facility in 2015, Holmes and Sunny Balwani constructed a Potemkin village of working equipment and clean conditions. The real lab was different.

The board is where the story gets dark.

Holmes assembled what was described as the most illustrious board in American corporate history: George Shultz (former Secretary of State), Henry Kissinger (former Secretary of State), William Perry (former Secretary of Defense), Sam Nunn (former Senator), Bill Frist (former Senator and heart surgeon), Jim Mattis (future Secretary of Defense), Gary Roughead (Admiral), Richard Kovacevich (former Wells Fargo CEO), and Riley Bechtel (former Bechtel CEO).

These were not medical experts. They were not technologists. They were military men and diplomats and bankers who had no mechanism to verify what they were being told.

Holmes recruited them with charisma, with conviction, with a compelling narrative. She spoke in the language of world-changing purpose. She wore black turtlenecks — Jobs-style — and spoke in a lower register than she actually used in private. She projected singular focus.

When Tyler Shultz — George Shultz's grandson — joined Theranos as an employee in 2013, he quickly discovered problems. He reported them internally. He was told to stop asking questions. He then reported them to the New York State Department of Health, under an alias, and eventually became John Carreyrou's key source at the Wall Street Journal.

Holmes fought back. She sent lawyers after him. She hired a reputation management firm to scrub WSJ coverage from Wikipedia. She had Boies Schiller Flexner — one of the most prestigious law firms in the country — send threatening letters to former employees.

Walgreens invested $350 million to retrofit 800 store locations for Theranos blood testing. Safeway did the same. These were not naive investors — they were sophisticated companies spending hundreds of millions of dollars after doing due diligence. They were still deceived.

The unraveling started with academics.

In February 2015, Stanford professor John Ioannidis — one of the most cited researchers in clinical medicine — published a piece in the Journal of the American Medical Association noting that Theranos had published no peer-reviewed research. Zero. For a company claiming to have revolutionized blood testing, this is significant.

In May 2015, University of Toronto professor Eleftherios Diamandis analyzed the published data and concluded that "most of the company's claims are exaggerated."

Then came Carreyrou.

In October 2015, the Wall Street Journal published its first investigation. It revealed that Theranos was using traditional machines for most tests, that the Edison had accuracy problems, and that the company had voided and corrected thousands of test results. Theranos called the reporting "factually and scientifically erroneous."

Holmes appeared at the WSJ conference four days later. The audience didn't push back.

The fallout came fast:

• The FDA inspected and found the nanotainer — Theranos's proprietary blood collection vial — was a Class II medical device requiring regulatory clearance, which Theranos had not obtained.
• CMS inspectors found the Newark, California lab posed "immediate jeopardy to patient health and safety." The specific case involved a warfarin test — a drug where getting the dosage wrong can kill.
• Walgreens suspended operations in January 2016. Then ended the partnership entirely in June.
• Forbes dropped the valuation to $800 million, then noted Holmes's stake was worth nothing.
• Theranos voided two years of Edison test results in May 2016.
• CMS banned Holmes and Balwani from owning or operating clinical laboratories for two years.
• Walgreens sued for breach of contract, seeking $140 million. Settled for less than $30 million.
• Arizona AG found the company had violated consumer protection law. Theranos refunded $4.65 million to every Arizona customer.
• In December 2017, Fortress Investment Group loaned Theranos $100 million at 4% equity, just to keep the company from going bankrupt.

In September 2018, Theranos shut down. "We are now out of time," wrote CEO David Taylor to shareholders.

Holmes was convicted in January 2022 on four counts of wire fraud and conspiracy. She was sentenced to 11 years and 3 months in federal prison. She reported to FPC Bryan in Texas in May 2023. In 2026, she's still there — fighting to cut more time off her sentence.

Balwani was convicted in July 2022 on all 12 counts. Twelve years and eleven months.

The film rights to John Carreyrou's book Bad Blood went to Jennifer Lawrence and Adam McKay.